Gapping up
In reaction to earnings/guidance:
- PL +11.3%, CNM +6.1%, RRX +2% (reaffirms outlook), ORCL +1.6%
Other news:
- AKRO +93.2% (reports Phase 2b HARMONY Study)
- AKUS +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
- CPRX +7.7% (to join S&P SmallCap 600)
- RCEL +4.8% (trial results for RECELL System)
- ANGI +3.4% (reports August performance metrics)
- LNG +3.3% (provides long-term plan targets; increases FY22 guidance; increases share repurchase authorization by $4 bln)
- ZYME +3% (reports preliminary Phase 1 results for Zanidatamab Zovodotin)
- UBS +2.8% (provides update on its 2022 capital returns to shareholders; raises dividend)
- APP +2.7% (APP confirms it does not intend to submit another proposal to combine with U and has withdrawn its initial proposal)
- AVIR +2.1% (to Advance Global Phase 3 Registrational Study of Bemnifosbuvir)
- RKLB +1.9% (preparing to launch its 30th Electron rocket and 150th satellite to space)
- IAC +1.9% (reports August performance metrics)
- SMR +1.4% (signs task order with KGHM to initiate deployment of first small modular reactor in Poland)
- PTON +1.2% (co-founders John Foley and Hisao Kushi step down; names new chairperson)
- BEN +1.1% (reports August AUM)
Analyst comments:
- AEG +2.3% (upgraded to Buy from Hold at Societe Generale)